Opioid Use Disorder (OUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Opioid Use Disorder (OUD) Market Outlook
Thelansis’s “Opioid Use Disorder (OUD)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Opioid Use Disorder (OUD) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Opioid Use
Disorder (OUD) Overview
Opioids
are chemicals that can be natural, semi-synthetic, or synthetic, and they
interact with the body and brain’s opioid receptors to diminish the sensation
of pain. While the terms opioids and opiates are often used synonymously,
opiates refer exclusively to natural substances derived from the poppy plant,
like morphine or heroin. Opioids, on the other hand, can be either naturally
occurring or synthetically produced in laboratories. The majority of opioids
are prescribed, though a significant number are also acquired illegally. It is
common for patients to develop opioid dependence after using opioids for a
short time, which can present as either physical or psychological dependence,
or both, leading to withdrawal symptoms if the opioid use is suddenly
discontinued. Opioid use disorder (OUD) can affect individuals across all
educational and socioeconomic strata. OUD is more likely in patients who lack
certain neurotransmitters such as dopamine, have first-degree relatives with
substance abuse disorders, or have been exposed to environments where opioid
use is prevalent.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment